139 related articles for article (PubMed ID: 2499443)
1. Effects of combined insulin-sulfonylurea therapy in type II patients.
Lewitt MS; Yu VK; Rennie GC; Carter JN; Marel GM; Yue DK; Hooper MJ
Diabetes Care; 1989 Jun; 12(6):379-83. PubMed ID: 2499443
[TBL] [Abstract][Full Text] [Related]
2. Concomitant insulin and sulfonylurea therapy in patients with type II diabetes. Effects on glucoregulation and lipid metabolism.
Osei K; O'Dorisio TM; Falko JM
Am J Med; 1984 Dec; 77(6):1002-9. PubMed ID: 6439036
[TBL] [Abstract][Full Text] [Related]
3. Combination insulin/glyburide therapy in type II diabetes mellitus. Effects on lipoprotein metabolism and glucoregulation.
Falko JM; Osei K
Am J Med; 1985 Sep; 79(3B):92-101. PubMed ID: 3931467
[TBL] [Abstract][Full Text] [Related]
4. Serum C-peptide levels determine glycemic responses in type II diabetic patients treated with combined insulin and sulfonylurea agent.
Osei K; Falko JM
Am J Med Sci; 1985 Apr; 289(4):148-53. PubMed ID: 3920907
[TBL] [Abstract][Full Text] [Related]
5. Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on glycemic control in non-insulin dependent diabetics poorly controlled with insulin alone.
Groop L; Harno K; Nikkilä EA; Pelkonen R; Tolppanen EM
Acta Med Scand; 1985; 217(1):33-9. PubMed ID: 3919531
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
DeFronzo RA; Goodman AM
N Engl J Med; 1995 Aug; 333(9):541-9. PubMed ID: 7623902
[TBL] [Abstract][Full Text] [Related]
7. Insulin-glyburide combination therapy for non-insulin-dependent diabetes mellitus: a long-term double-blind, placebo-controlled trial.
Casner PR
Clin Pharmacol Ther; 1988 Nov; 44(5):594-603. PubMed ID: 3141099
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects.
Riddle MC; Hart JS; Bouma DJ; Phillipson BE; Youker G
Diabetes Care; 1989 Oct; 12(9):623-9. PubMed ID: 2507265
[TBL] [Abstract][Full Text] [Related]
9. Comparison of morning or bedtime insulin with and without glyburide in secondary sulfonylurea failure.
Soneru IL; Agrawal L; Murphy JC; Lawrence AM; Abraira C
Diabetes Care; 1993 Jun; 16(6):896-901. PubMed ID: 8325203
[TBL] [Abstract][Full Text] [Related]
10. Effects of combination therapy with glyburide and insulin on serum lipid levels in NIDDM patients with secondary sulfonylurea failure.
Karlander SG; Gutniak MK; Efendic S
Diabetes Care; 1991 Nov; 14(11):963-7. PubMed ID: 1797509
[TBL] [Abstract][Full Text] [Related]
11. Glyburide in non-insulin-dependent diabetes. Its therapeutic effect in patients with disease poorly controlled by insulin alone.
Lardinois CK; Liu GC; Reaven GM
Arch Intern Med; 1985 Jun; 145(6):1028-32. PubMed ID: 3923961
[TBL] [Abstract][Full Text] [Related]
12. Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind, randomized clinical trial.
Schade DS; Mitchell WJ; Griego G
JAMA; 1987 May; 257(18):2441-5. PubMed ID: 3106656
[TBL] [Abstract][Full Text] [Related]
13. Glyburide and glipizide in treatment of diabetic patients with secondary failures to tolazamide or chlorpropamide.
Lev JD; Zeidler A; Kumar D
Diabetes Care; 1987; 10(6):679-82. PubMed ID: 3123183
[TBL] [Abstract][Full Text] [Related]
14. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
Hollander PA; Schwartz SL; Gatlin MR; Haas SJ; Zheng H; Foley JE; Dunning BE
Diabetes Care; 2001 Jun; 24(6):983-8. PubMed ID: 11375357
[TBL] [Abstract][Full Text] [Related]
15. Maintenance of sulfonylurea responsiveness in NIDDM. Randomized double-blind study of intermittent glyburide therapy.
Grunberger G
Diabetes Care; 1992 May; 15(5):696-9. PubMed ID: 1516489
[TBL] [Abstract][Full Text] [Related]
16. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients.
Simpson HC; Sturley R; Stirling CA; Reckless JP
Diabet Med; 1990 Feb; 7(2):143-7. PubMed ID: 2137755
[TBL] [Abstract][Full Text] [Related]
17. Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea.
Riddle M; Hart J; Bingham P; Garrison C; McDaniel P
Am J Med Sci; 1992 Mar; 303(3):151-6. PubMed ID: 1595776
[TBL] [Abstract][Full Text] [Related]
18. Treatment of type I diabetes with a combination of glyburide and insulin.
Gums JG; Curry RW; Montes de Oca G; Skluth HA; Reynolds LR
Ann Pharmacother; 1992 Jun; 26(6):757-62. PubMed ID: 1611155
[TBL] [Abstract][Full Text] [Related]
19. Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide.
Roach ; Koledova E; Metcalfe S; Hultman C; Milicevic Z;
Clin Ther; 2001 Oct; 23(10):1732-44. PubMed ID: 11726007
[TBL] [Abstract][Full Text] [Related]
20. Repaglinide versus glyburide: a one-year comparison trial.
Marbury T; Huang WC; Strange P; Lebovitz H
Diabetes Res Clin Pract; 1999 Mar; 43(3):155-66. PubMed ID: 10369424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
